Submit or Track your Manuscript LOG-IN

A New Species of the Genus Otacilia

Otacilia dadongshanica sp. nov., male holotype.

A New Species of the Genus Otacilia

Otacilia dadongshanica sp. nov., male holotype.

Celecoxib and Cisplatin Synergistically Inhibit Oral Cancer Cell Proliferation Via Modulating the NOTCH 1 Signalling Pathway

Celecoxib and Cisplatin Synergistically Inhibit Oral Cancer Cell Proliferation Via Modulating the NOTCH 1 Signalling Pathway

Zuhair M. Mohammedsaleh1*, Mamdoh S. Moawadh1, Fayez M. Saleh2, Mohammed M. Jalal1, Abdulaziz S Al-Otaibi1, Nizar H. Saeedi1, Rathinasamy Baskaran3, Chih-Yang Huang4 and V. Bharath Kumar5*

ABSTRACT

Oral squamous cell carcinoma is the sixth most common cancer worldwide. Though there are significant improvements in diagnosis and treatment, the outcome is still very low. Thus, the development of novel therapeutic approaches is needed. In this study, we aimed to identify the inhibitory effect of celecoxib (CXB), cisplatin (Cis) and the combination of CXB and Cis and to explore the potential molecular mechanisms involved in oral cancer cells (OC-3 and SCC-9). MTT assay was used to check the cell viability, cell migration and invasion was performed to evaluate the metastasis and western blot to check the protein expression. The results showed that the combination of CXB and Cis synergistically inhibited cell proliferation, migration and invasion of OC-3 cells. The notch signalling pathway plays an oncogenic role in tongue squamous cell carcinoma. We observed that treatment with CXB and Cis decreased NOTCH1, JAG1, Pre 2, and ADAM9 expression and increased Numb protein expression. Our study demonstrated that Notch signalling is dysregulated in human OSCC and plays a role in cell proliferation.

To share on other social networks, click on any share button. What are these?

Pakistan Journal of Zoology

November

Pakistan J. Zool., Vol. 56

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe